DSM and DuPont announce joint venture in surgical biomedical materials
(Thomson Reuters ONE) -
Royal DSM N.V., the global Life Sciences and Materials Sciences company
headquartered in the Netherlands, and DuPont announce an agreement to form a
joint venture to develop, manufacture and commercialize advanced surgical
biomedical materials, pending European Union regulatory approval. The joint
venture will be named Actamax Surgical Materials LLC. Under the joint venture
agreement, DSM and DuPont will each share a 50 percent interest.
The joint venture will address the market for surgical sealants, adhesion
barriers and tissue adhesives. This is a large and underserved market of over
100 million annual surgical procedures worldwide. The outcome of many surgical
procedures could be positively impacted using next-generation materials under
development by the joint venture.
Actamax Surgical Materials LLC will build a comprehensive biomedical product
portfolio based on several patent-protected biodegradable hydrogel technologies.
The early technology development was completed utilizing DuPont materials
science and biotechnology capabilities. Commercialization will rely on the
medical polymer processing and manufacturing capabilities of DSM.
The activities of the joint venture fit with the DSM biomedical materials
portfolio in which the company, through its DSM Biomedical unit, has rapidly
built a leading position in the past few years. Actamax Surgical Materials LLC
is a strategic component of the DuPont Applied BioSciences business, which
integrates biotechnology with other sciences to create products that can
transform large, addressable markets. The joint venture will focus on the
clinical validation of the products and technology and commercialization will
include manufacture and sale of proprietary products as well as the
establishment of joint development relationships with leading device companies.
"The cooperation with DuPont is a great way to further boost our activities in
the biomedical field," said Christophe J. Dardel, president DSM Biomedical. "In
line with our open innovation strategy, this will allow us to combine the
strengths of two leading companies to develop solutions to better address
patient needs through material innovations."
"Our platform of technologies will offer physicians and patients improved
outcomes of surgery that will prevent post-operative complications while
reducing health care costs," said John Ranieri, vice president DuPont Applied
BioSciences. "Actamax will deliver a number of products that can be optimized
for different surgical situations and clinical needs. The success DSM has had
in the biomedical materials market makes them an ideal strategic partner for us
to commercialize our technology portfolio."
For more information, visit www.actamax.com .
DuPont
DuPont (www.dupont.com) is a science-based products and services company.
Founded in 1802, DuPont puts science to work by creating sustainable solutions
essential to a better, safer, healthier life for people everywhere. Operating
in more than 90 countries, DuPont offers a wide range of innovative products and
services for markets including agriculture and food; building and construction;
communications; and transportation.
DSM - the Life Sciences and Materials Sciences Company
Royal DSM N.V. creates solutions that nourish, protect and improve performance.
Its end markets include human and animal nutrition and health, personal care,
pharmaceuticals, automotive, coatings and paint, electrical and electronics,
life protection and housing. DSM manages its business with a focus on the triple
bottom line of economic performance, environmental quality and social
responsibility, which it pursues simultaneously and in parallel. DSM has annual
net sales of about ? 8 billion and employs some 22,700 people worldwide. The
company is headquartered in the Netherlands, with locations on five continents.
DSM is listed on Euronext Amsterdam. More information:www.dsm.com
For more information:
DSM Corporate Communications DSM Investor Relations
Herman Betten Hans Vossen
tel. +31 (0) 45 5782017 tel. +31 (0) 45 5782864
fax +31 (0) 45 5740680 fax +31 (0) 45 5782595
e-mailmedia.relations(at)dsm.com e-mailinvestor.relations(at)dsm.com
DuPont Communications DuPont Investor Relations
Michelle Reardon Jeanmarie Desmond
Tel +1-302-695-7068 Tel +1-302-774-2229
michelle.s.reardon(at)usa.dupont.com jeanmarie.f.desmond(at)usa.dupont.com
[HUG#1446269]
Press release-pdf:
http://hugin.info/130663/R/1446269/389260.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: DSM N.V. via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 23.09.2010 - 08:15 Uhr
Sprache: Deutsch
News-ID 42959
Anzahl Zeichen: 0
contact information:
Town:
Heerlen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 194 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DSM and DuPont announce joint venture in surgical biomedical materials"
steht unter der journalistisch-redaktionellen Verantwortung von
DSM N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
